Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
NEW YORK - Morgan Stanley & Co. LLC disclosed on Monday its trading activity in Avadel Pharmaceuticals plc (NASDAQ:AVDL) ordinary shares, according to a regulatory filing with the Irish Takeover Panel.
The investment bank, acting as an exempt principal trader with recognized intermediary status in a client-serving capacity, reported transactions conducted on November 28, 2025.
According to the disclosure, Morgan Stanley purchased 78,613 Avadel ordinary shares at prices ranging from $21.42 to $21.54 per share. The firm also sold 78,320 shares at prices between $21.40 and $21.51.
The filing indicates Morgan Stanley is connected to Avadel Pharmaceuticals in relation to an unspecified offer or potential transaction. No cash-settled derivative transactions, options trading, or other dealings were reported in the disclosure.
The dealing disclosure was made under Rule 38.5(a) of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, which requires certain disclosures from exempt principal traders connected to companies involved in takeover situations.
The information was submitted through RNS, the news service of the London Stock Exchange, as required for public disclosures under Rule 38 of the Irish Takeover Rules.
This article is based on a regulatory disclosure statement filed by Morgan Stanley.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.